Xencor(XNCR)
PASADENA, CABiotechnology
Focus: Xencor is a public biotechnology company specializing in antibody discovery and engineering, focused on oncology and immunology therapeutics. The company operates as a mid-cap biotech with a public market presence (NASDAQ: XNCR) and a revenue base of ~$175M.
Profile data last refreshed 12h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Xencor
AI assessmentNot HiringNo open roles listed right now. Follow Xencor to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Xencor's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
34 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$175M
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT05585034Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1Help build intelligence for Xencor
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.